Teva Pharmaceutical Industries Limited

Teva Pharmaceutical is a global generics and specialty pharma with a long-running turnaround from opioid litigation and generics-cycle pressure. Shares are +102% TTM at $36.44, and the recent set of catalysts has stabilized the story.

• Revenue and EPS are stable and cash-generative: quarterly revenue ran $4.48B / $4.71B / $3.98B / $4.14B, quarterly EPS at $0.38 / $0.42 / $0.32 / $-0.49 (one-time item) — analysts model $16.6B and $2.00 EPS for the full year, so at $36 the stock is at roughly 18x forward, defensible for a turnaround.
• The Pivot to Growth strategy is producing dated catalysts: the proposed acquisition of a novel neuroscience product reinforces the disciplined business-development approach, and Ecopipam winning FDA Priority Review tag in pediatric Tourette Syndrome is exactly the kind of Priority-Review qualifier that changes the timeline math.
• The legal/IP side is quietly clearing: Aurinia Pharmaceuticals and Teva settled the patent dispute for the kidney disease drug — that's the kind of overhang resolution that removes tape risk without needing a specific new catalyst to keep the momentum.

A Nov 4 print that shows generics revenue holding, biosimilars growth, and any Ecopipam or novel-neuroscience-BD commentary extends the run; a specific generics-price crash, an opioid-settlement escalation, or a critical Ecopipam data slippage is what caps the tape.